This is an overview of STATA programs used in the analysis for “Knowledge of and attitudes toward aducanumab among older Americans in the weeks following F.D.A approval for the treatment of Alzheimer’s disease,” by Julie Zissimopoulos, Mireille Jacobson, Yi Chen, and Sue Borson published in JAMA Network Open in 2022.

**Describe Characteristics**

Characteristics.do

* Source data: UAS405.dta
* Describes characteristics and explore recoding

**Analysis**

Aducanumab\_analysis.do

* Source data: UAS405.dta
* 1) Recodes aducanumab-related response and socio-demographic variables, 2) describes knowledge of & attitude toward aducanumab, and 3) Model increasing chance of screening, receiving aducanumab if have AD, and correct answers to T/F questions